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Introduction
============

While it is generally accepted that coronary revascularisation reduces the risk of death and myocardial infarction compared with initial medical treatment among patients with acute coronary syndromes,[@ref1] [@ref2] the prognostic benefit is less well established among patients with stable coronary artery disease.[@ref3] [@ref4] Compared with medical treatment, coronary artery bypass grafting has been shown to convey a survival advantage[@ref5]; conversely, the benefit of percutaneous coronary interventions remains debatable.[@ref6] [@ref7] [@ref8] None of the individual trials comparing medical treatment with percutaneous coronary intervention have shown a survival advantage, and meta-analyses revealed conflicting results, with some reporting no difference[@ref9] [@ref10] and others suggesting a modest benefit.[@ref10] [@ref11] [@ref12] Notwithstanding, none of the randomised trials has been adequately powered to deal with survival, whereas treatment effects were reduced owing to crossover to revascularisation in a sizable proportion of patients and exclusion of high risk patients based on angiographically defined extent of coronary artery disease.[@ref13] [@ref14] Moreover, revascularisation techniques have matured over time. Nowadays, coronary artery bypass grafting systematically employs the internal mammary artery with proved long term patency and survival benefit.[@ref15] [@ref16] Similarly, percutaneous coronary intervention has evolved with important historical transitions from the era of balloon angioplasty,[@ref17] over bare metal stents,[@ref18] [@ref19] [@ref20] to early generation, Food and Drug Administration approved drug eluting stents,[@ref21] [@ref22] [@ref23] [@ref24] followed more recently by new generation drug eluting stents.[@ref25] [@ref26] [@ref27]

A large number of trials compared the different revascularisation strategies, including coronary artery bypass grafting,[@ref28] [@ref29] balloon angioplasty,[@ref30] [@ref31] and percutaneous coronary intervention with bare metal stents[@ref13] or with various FDA approved drug eluting stents against medical treatment,[@ref32] as well as different revascularisation strategies head to head.[@ref26] [@ref33] [@ref34]

Network meta-analysis allows a unified analysis of the entire set of available trials by combining all direct within trial comparisons with indirect between trial comparisons of interventions constructed from trials that have one intervention in common, while fully respecting randomisation.[@ref35] [@ref36] We established a collaborative group of investigators consisting of cardiovascular surgeons and interventional and non-invasive cardiologists with expertise in the specialty of revascularisation, and conducted a network meta-analysis of all available trials to provide novel evidence in view of several recently reported trials and major technological advances in revascularisation and medical treatment.

Methods
=======

Literature search and study selection
-------------------------------------

We searched Medline and Embase from 1980 to June 2013, using the methodological filters proposed by the Cochrane Collaboration to search for randomised clinical trials (see supplementary appendix). In addition, we hand searched reference lists of relevant reviews. Two investigators (GS, SS) assessed reports for eligibility. To be included in the analysis, studies had to be randomised controlled trials in patients with symptomatic or asymptomatic stable coronary artery disease or in unselected patient populations. Trials had to have a clinical follow-up duration of at least six months and were required to randomise at least 100 patients per trial arm. Patients had to be randomised to medical treatment, coronary artery bypass grafting, or percutaneous coronary intervention using balloon angioplasty, bare metal stents, early generation stent systems (paclitaxel eluting Taxus stent (Boston Scientific, Natick, MA), sirolimus eluting Cypher stent (Cordis, Miami Lakes, FL), zotarolimus eluting Endeavor stent (Medtronic Cardiovascular, Santa Rosa, CA)) or new generation stent systems (zotarolimus eluting Resolute stent (Medtronic Cardiovascular, Santa Rosa, CA) and everolimus eluting Xience/Promus stent (Abbott Vascular, Santa Clara, CA and Boston Scientific, Natick, MA)) approved by the FDA. We excluded trials in patients with acute myocardial infarction (ST segment elevation myocardial infarction or non-ST segment elevation myocardial infarction) and symptom onset less than 72 hours, trial arms with polymer or carbon coated bare metal stents, and trial arms with non-FDA approved drug eluting stents.

Data collection and outcomes
----------------------------

Four investigators (MdN, MGS, AM, or AR) independently extracted data, with disagreement resolved in consultation with another investigator (SS, GS, or PJ). We prespecified all cause mortality as the primary outcome, and myocardial infarction, a composite of death or myocardial infarction, and subsequent revascularisation as secondary outcomes. Subsequent revascularisation was defined as percutaneous or surgical revascularisation of the target lesion. If rates of target lesion revascularisation were not reported, we used rates of target vessel revascularisation or any revascularisation as a proxy measure. We extracted outcome data at the follow-up closest to five years. We assessed three key domains of internal validity, concealment of allocation, blind adjudication of outcomes, and the inclusion of all randomised participants in the analysis according to the intention to treat principle (see supplementary appendix).

Statistical analysis
--------------------

The network meta-analysis was based on a bayesian random effects Poisson regression model, which preserves randomised treatment comparisons within trials.[@ref36] [@ref37] [@ref38] [@ref39] The model uses numbers of patients experiencing an event and accumulated patient years to estimate rate ratios. The specification of nodes in the network were based on the randomised intervention or in case of strategy trials, such as COURAGE[@ref13] or FAME-2,[@ref32] on the intervention received by the majority of patients in a trial arm. Analyses were performed using Markov-Chain Monte-Carlo methods. The prior distribution for treatment effects was minimally informative: a normal distribution with a mean of 1 and a 95% reference range from 0.01 to 100 on a rate ratio scale. The prior for the between trial variance τ^2^, which we assumed to be equal across comparisons, was based on empirical evidence derived from semi-objective outcomes of head to head comparisons[@ref40]: a log normal distribution with a geometric mean of τ^2^ of 0.04 and a 95% reference range from 0.001 to 1.58. Rate ratios were estimated from the median and corresponding 95% credibility intervals from the 2.5th and 97.5th centiles of the posterior distribution. We performed primary analyses in all trials; secondary analyses were restricted to contemporary trials with start of patient enrolment in 1999 or later, which corresponds to the start of patient enrolment in COURAGE.[@ref13] We performed sensitivity analyses restricted to trials with adequate concealment of allocation; restricted to trials with blinded adjudication of events; restricted to trials with analysis according to the intention to treat principle; excluding trials that assigned patients to revascularisation with coronary artery bypass grafting; excluding "all comer" trials in unselected populations and trials in patients post-myocardial infarction, defined as patients with a history of myocardial infarction more than 72 hours to three months before randomisation; excluding trials with less than two years' follow-up; excluding trials with more than 10% of patients lost to follow-up; and performing bayesian random effects meta-analyses for all available direct randomised comparisons. In additional sensitivity analyses, we used different priors for τ^2^ and used frequentist network meta-analyses to calculate rate ratios and risk ratios without the use of priors. To examine the data for small study effects, we constructed comparison adjusted funnel plots (see supplementary appendix). Convergence was deemed to be achieved if plots of the Gelman-Rubin statistics[@ref41] indicated that widths of pooled runs and individual runs stabilised around the same value and their ratio was around 1. Given these criteria, we based our calculations on the 20 001 to 50 000 iterations, discarding the first 20 000 iterations as burn-in. We examined the inconsistency of the network by calculating loop specific inconsistency factors, and an omnibus test to derive an overall P value for inconsistency, which took into account multiple testing of potentially correlated inconsistency factors.[@ref42] Inconsistent loops were examined individually for sources of inconsistency. Statistical heterogeneity between trials was estimated from the median between trial variance τ^2^ observed in the posterior distribution, and goodness of fit of the model was assessed using residual deviances.[@ref38] Analyses were done in Stata 12.1 and WinBUGS 1.4.

Results
=======

Characteristics of trials and patients
--------------------------------------

Supplemental figure 1 presents the flow chart of the study and summarises the process of identifying trials. We screened the titles and abstracts of 14 888 potentially eligible reports, examined the full text of 620 articles, and identified 399 articles on 100 trials that met our inclusion criteria. Table 1[](#tbl1){ref-type="table"} presents the characteristics of the included trials. The characteristics of the patients and their diseases in the eligible studies are summarised in the supplementary appendix and the characteristics of treatment arms are summarised in table 2[](#tbl2){ref-type="table"}. Figure 1[](#fig1){ref-type="fig"} shows the network of evidence. The bare metal stent was investigated most (50 trials) and compared with seven different interventions, whereas the zotarolimus eluting (Resolute) stent was evaluated least (four trials) and compared with three different interventions. For the primary endpoint all cause mortality, the sirolimus eluting stent and bare metal stent had the largest number of patient years (45 879 and 45 467, respectively) and the zotarolimus eluting (Resolute) stent the lowest number (3384 patient years). Overall, 93 553 patients were randomised and we included follow-up of 260 090 patient years in the analysis of the primary endpoint.

![**Fig 1** Network of comparisons included in analyses. Circle size is proportional to number of randomised patients and reflects sample size, whereas line width is proportional to number of comparisons. CABG=coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; BMS=bare metal stents; PES=paclitaxel eluting stent; SES=sirolimus eluting stent; E-ZES=zotarolimus eluting (Endeavor) stent; R-ZES=zotarolimus eluting (Resolute) stent; EES=everolimus eluting stent](wins015885.f1_default){#fig1}

###### 

 Characteristics of randomised trials. Values are medians (ranges) unless stated otherwise

  Characteristics                                               Total (n=100)
  ------------------------------------------------------------- ------------------
  No of patients randomised                                     510 (200-8709)
  Average age (years)                                           62 (51-69)
  \% women                                                      24 (0-42)
  \% with multivessel disease                                   55 (34-80)
  Left ventricular ejection fraction (%)                        59.5 (56-61.2)
  \% of patients with diabetes                                  23 (16-31)
  Year of publication                                           2007 (1982-2013)
  Intervention arms (No of trials/No of randomised patients):   
   Medical treatment                                            15 (7010)
   Coronary artery bypass grafting                              22 (8920)
   Percutaneous transluminal coronary angioplasty               29 (7609)
   Bare metal stent                                             50 (16 042)
   Paclitaxel eluting stent                                     27 (11 541)
   Sirolimus eluting stent                                      39 (19 781)
   Zotarolimus eluting (Endeavor) stent                         8 (8937)
   Rotarolimus eluting (Resolute) stent                         4 (2285)
   Everolimus eluting stent                                     17 (13 272)
  Methodological characteristics (No (%) of trials):            
   Adequate allocation concealment                              71 (71)
   Blind event adjudication                                     56 (56)
   Intention to treat analysis performed                        69 (69)

###### 

 Characteristics of treatment arms

  Treatment           Follow-up (patient years)\*   No of events                 
  ------------------- ----------------------------- -------------- ------ ------ ------
  Medical treatment   30 628                        857            541    967    1709
  CABG                38 709                        970            553    1170   556
  PTCA                17 678                        296            451    706    2164
  BMS                 45 467                        852            946    1628   2873
  PES                 27 592                        567            663    1104   1203
  SES                 45 879                        909            1321   1752   1434
  E-ZES               27 134                        445            788    683    719
  R-ZES               3384                          55             130    180    144
  EES                 23 619                        395            403    746    817

CABG=coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; BMS=bare metal stent; PES=paclitaxel eluting stent; SES=sirolimus eluting stent; E-ZES=zotarolimus eluting (Endeavor) stent; R-ZES=zotarolimus eluting (Resolute) stent; EES=everolimus eluting stent.

\*For the primary endpoint all cause death.

In general, trials were considered to be of high methodological quality. Appropriate methods of allocation concealment were described for 71 trials (71%). Fifty six trials (56%) reported blind adjudication of clinical outcomes, and for 69 trials (69%) we were able to include all randomised patients into the analysis according to the intention to treat principle. Supplementary table 2 presents the raw numbers of events separately for each trial at the follow-up closest to five years. Supplementary table 3 provides a breakdown of the number of patients, events, and accumulated patient years by intervention. Figure 2[](#fig2){ref-type="fig"} provides the cumulative number of patients randomly assigned to different types of intervention over time. Figure 3[](#fig3){ref-type="fig"} presents the rate ratios of clinical outcomes of revascularisation compared with medical treatment.

![**Fig 2** Accumulation of randomised evidence according to comparison over time. Cumulative number of patients randomly assigned to different types of intervention according to start of patient enrolment in each trial is presented. CABG=coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; BMS=bare metal stent; DES=drug eluting stent](wins015885.f2_default){#fig2}

![**Fig 3** Estimated rate ratios (95% credibility intervals) for mortality, myocardial infarction, the composite of death or myocardial infarction, and subsequent revascularisation from network meta-analyses for different revascularisation modalities compared with medical treatment---overall analyses. Square size is proportional to statistical precision of estimates. CABG=coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; BMS=bare metal stents; PES=paclitaxel eluting stent; SES=sirolimus eluting stent; E-ZES=zotarolimus eluting (Endeavor) stent; R-ZES=zotarolimus eluting (Resolute) stent; EES=everolimus eluting stent](wins015885.f3_default){#fig3}

All cause mortality
-------------------

Ninety five trials including 93 553 randomised patients and 5346 accumulated events contributed to the analysis of all cause mortality. Compared with a strategy of initial medical treatment, revascularisation using coronary artery bypass grafting reduced all cause mortality by 20% (rate ratio 0.80, 95% credibility interval 0.70 to 0.91). Percutaneous coronary intervention with new generation drug eluting stents, but no other percutaneous coronary intervention technology, was also associated with reduced mortality compared with medical treatment (everolimus eluting: 0.75, 0.59 to 0.96; zotarolimus eluting (Resolute): 0.65, 0.42 to 1.00). The estimated rate ratios for mortality were below 1, but inconclusive for revascularisation with balloon angioplasty (0.85, 0.68 to 1.04), bare metal stents (0.92, 0.79 to 1.05), and early generation drug eluting stents (paclitaxel eluting: 0.92, 0.75 to 1.12; sirolimus eluting: 0.91, 0.75 to 1.10; zotarolimus eluting (Endeavor): 0.88, 0.69 to 1.10).

Myocardial infarction
---------------------

Ninety two trials including 90 472 randomised patients contributed to the endpoint analysis of myocardial infarction (see supplementary tables 2 and 3). Overall, 5796 events were reported during 243 031 patient years and contributed to the analysis of myocardial infarction. Revascularisation using coronary artery bypass grafting compared with medical treatment reduced myocardial infarction during the observational period by 21% (0.79, 0.63 to 0.99). All percutaneous coronary interventions, except bare metal stent (1.04, 0.84 to 1.27) and paclitaxel eluting stent (1.18, 0.88 to 1.54), showed evidence for a relevant but inconclusive reduction of myocardial infarction, with point estimates below 1 for balloon angioplasty (0.88, 0.70 to 1.11), sirolimus eluting stent (0.94, 0.71 to 1.22), zotarolimus eluting (Endeavor) stent (0.80, 0.56 to 1.10), zotarolimus eluting (Resolute) stent (0.82, 0.52 to 1.26), and everolimus eluting stent (0.75, 0.55 to 1.01).

Composite of death or myocardial infarction
-------------------------------------------

Eighty eight trials including 89 373 randomised patients and 8936 accumulated events during 233 030 patient years contributed to the analysis of the composite endpoint death or myocardial infarction (see supplementary tables 2 and 3). Compared with medical treatment, revascularisation using coronary artery bypass grafting, balloon angioplasty, and everolimus eluting stent was associated with a significant reduction of death or myocardial infarction by 19% (0.81, 0.70 to 0.94), 17% (0.83, 0.70 to 0.97), and 22% (0.78, 0.63 to 0.96), respectively. No other percutaneous revascularisation technology was effective in showing a significant reduction in death or myocardial infarction, although point estimates were in favour of revascularisation with sirolimus eluting stent (0.96, 0.79 to 1.13), zotarolimus eluting (Endeavor) stent (0.85, 0.67 to 1.05), and zotarolimus eluting (Resolute) stent (0.81, 0.59 to 1.10).

Subsequent revascularisation
----------------------------

Ninety four trials in 90 282 patients contributed to the analysis of subsequent revascularisation (see supplementary tables 2 and 3). Subsequent coronary revascularisation events were reported in 11 619 patients during the follow-up duration of 234 693 patient years and contributed to the analysis of subsequent revascularisation.

Compared with medical treatment, revascularisation with coronary artery bypass grafting was effective in reducing subsequent revascularisation by 84% (0.16, 0.13 to 0.20). Revascularisation using coronary stents was associated with a reduction in subsequent revascularisation for bare metal stent (0.44, 0.59 to 0.82), paclitaxel eluting stent (0.44, 0.35 to 0.55), sirolimus eluting stent (0.29, 0.24 to 0.36), zotarolimus eluting (Endeavor) stent (0.38, 0.29 to 0.51), zotarolimus eluting (Resolute) stent (0.26, 0.17 to 0.40), and everolimus eluting stent (0.27, 0.21 to 0.35). Revascularisation with balloon angioplasty showed similar risks of subsequent revascularisation compared with medical treatment (0.97, 0.82 to 1.16).

Restriction to contemporary trials
----------------------------------

Figure 4[](#fig4){ref-type="fig"} presents results from analyses restricted to 88 contemporary trials which were initiated in 1999 or later, in 85 720 patients. Compared with the main analysis, point estimates of the rate ratio of all cause mortality moved closer to the null effect line, and 95% credibility intervals became wider, with a rate ratio of 0.85 for coronary artery bypass grafting (0.72 to 1.00), 0.82 for everolimus eluting stent (0.65 to 1.03), and 0.71 for zotarolimus eluting (Resolute) stent (0.46 to 1.11) compared with medical treatment. For myocardial infarction, the rate ratio for coronary artery bypass grafting moved towards more benefit (0.48, 0.37 to 0.64), and results became statistically more robust for the everolimus eluting stent (0.73, 0.57 to 0.95). For the composite of death or myocardial infarction and for revascularisation, results were similar to the main analysis.

![**Fig4** Estimated rate ratios (95% credibility intervals) for mortality, myocardial infarction, the composite of death or myocardial infarction, and subsequent revascularisation from network meta-analyses for different revascularisation modalities compared with medical treatment---secondary analyses of contemporary trials initiated in 1999 or later. Square size is proportional to statistical precision of estimates. CABG=coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; BMS=bare metal stents; PES=paclitaxel eluting stent; SES=sirolimus eluting stent; E-ZES=zotarolimus eluting (Endeavor) stent; R-ZES=zotarolimus eluting (Resolute) stent; EES=everolimus eluting stent](wins015885.f4_default){#fig4}

Additional analyses
-------------------

Supplementary table 4 presents rankings of different interventions compared with medical treatment in analyses of all trials, and supplementary table 5 shows the rankings in analyses of contemporaneous trials only. Table 3[](#tbl3){ref-type="table"} presents results of sensitivity analyses. Point estimates of treatment effects were similar to those derived for the main analysis for all outcomes and interventions, and overlapping 95% credibility intervals indicated that estimates from all sensitivity analyses, including conventional random effects meta-analyses of pairwise comparisons, were compatible with the main analysis. Supplementary table 6 presents estimated rate ratios of all possible comparisons from conventional meta-analysis of direct randomised comparisons and network meta-analysis; estimates from network and conventional meta-analysis, where available, were compatible. Supplementary figure 2 presents comparison adjusted funnel plots, without evidence of asymmetry. Supplementary table 7 presents results based on the use of different priors in bayesian analyses and frequentist network meta-analyses using rate ratios or risk ratios. Estimates remained robust to the use of different assumptions.

###### 

 Sensitivity analyses

  Outcomes by interventions         Network meta-analysis       Conventional meta-analysis\*                                                                                                                                                                           
  --------------------------------- --------------------------- ------------------------------ --------------------------- --------------------------- --------------------------- --------------------------- --------------------------- --------------------------- ---------------------
  All cause mortality:              67 trials with 195 142 PY   55 trials with 201 157 PY      66 trials with 206 937 PY   73 trials with 180 269 PY   77 trials with 174 343 PY   76 trials with 217 371 PY   54 trials with 230 503 PY   95 trials with 260 090 PY   
   CABG *v* medical treatment       0.83 (0.69 to 0.99)         0.87 (0.73 to 1.04)            0.84 (0.73 to 0.95)         ---                         0.81 (0.70 to 0.93)         0.75 (0.64 to 0.87)         0.79 (0.69 to 0.90)         0.80 (0.70 to 0.91)         0·77 (0.57 to 0.98)
   PTCA *v* medical treatment       0.92 (0.73 to 1.15)         0.88 (0.64 to 1.22)            0.91 (0.73 to 1.12)         0.85 (0.63 to 1.15)         0.85 (0.68 to 1.05)         0.82 (0.65 to 1.02)         0.81 (0.64 to 1.02)         0.85 (0.68 to 1.04)         0·66 (0.25 to 1.56)
   BMS *v* medical treatment        0.96 (0.77 to 1.19)         0.98 (0.83 to 1.15)            0.94 (0.80 to 1.09)         0.95 (0.78 to 1.13)         0.92 (0.77 to 1.06)         0.91 (0.74 to 1.09)         0.94 (0.81 to 1.09)         0.92 (0.79 to 1.05)         0·99 (0.74 to 1.26)
  Early generation DES:                                                                                                                                                                                                                                                
   PES *v* medical treatment        0.93 (0.72 to 1.19)         0.95 (0.75 to 1.20)            1.01 (0.80 to 1.26)         0.92 (0.69 to 1.20)         0.94 (0.74 to 1.18)         0.89 (0.70 to 1.10)         0.96 (0.78 to 1.18)         0.92 (0.75 to 1.12)         ---
   SES *v* medical treatment        0.87 (0.67 to 1.13)         0.94 (0.75 to 1.15)            0.95 (0.76 to 1.19)         0.91 (0.69 to 1.17)         1.00 (0.79 to 1.24)         0.91 (0.72 to 1.13)         0.94 (0.76 to 1.13)         0.91 (0.75 to 1.10)         ---
   E-ZES *v* medical treatment      0.89 (0.67 to 1.18)         0.91 (0.70 to 1.15)            0.95 (0.73 to 1.25)         0.88 (0.65 to 1.16)         0.79 (0.57 to 1.11)         0.85 (0.65 to 1.09)         0.91 (0.71 to 1.15)         0.88 (0.69 to 1.10)         ---
  New generation DES:                                                                                                                                                                                                                                                  
   R-ZES *v* medical treatment      0.65 (0.41 to 1.03)         0.68 (0.43 to 1.07)            NA                          0.65 (0.42 to 1.02)         NA                          0.65 (0.41 to 1.02)         0.65 (0.38 to 1.11)         0.65 (0.42 to 1.00)         ---
   EES *v* medical treatment        0.76 (0.58 to 1.02)         0.79 (0.62 to 1.02)            0.83 (0.63 to 1.07)         0.75 (0.56 to 1.00)         0.63 (0.45 to 0.90)         0.74 (0.56 to 0.95)         0.81 (0.63 to 1.03)         0.75 (0.59 to 0.96)         0.33 (0.03 to 3.16)
  Myocardial infarction:            65 trials with 183 637 PY   55 trials with 194 710 PY      63 trials with 194 515 PY   75 trials with 182 347 PY   75 trials with 158 564 PY   74 trials with 203 166 PY   50 trials with 214 188 PY   92 trials with 243 031 PY   
   CABG *v* medical treatment       0.77 (0.53 to 1.10)         0.69 (0.51 to 0.95)            0.80 (0.62 to 1.02)         ---                         0.80 (0.63 to 1.03)         0.78 (0.59 to 1.01)         0.77 (0.58 to 1.01)         0.79 (0.63 to 0.99)         0.69 (0.23 to 1.89)
   PTCA *v* medical treatment       0.92 (0.67 to 1.27)         0.92 (0.67 to 1.26)            0.89 (0.69 to 1.15)         0.98 (0.79 to 1.22)         0.88 (0.68 to 1.12)         0.89 (0.68 to 1.15)         0.82 (0.59 to 1.13)         0.88 (0.70 to 1.11)         0.87 (0.34 to 2.30)
   BMS *v* medical treatment        1.02 (0.73 to 1.38)         1.04 (0.81 to 1.29)            1.04 (0.83 to 1.30)         1.11 (0.94 to 1.32)         1.01 (0.80 to 1.25)         1.07 (0.81 to 1.38)         1.02 (0.77 to 1.32)         1.04 (0.84 to 1.27)         1.07 (0.63 to 1.50)
  Early generation DES:                                                                                                                                                                                                                                                
   PES *v* medical treatment        1.14 (0.79 to 1.67)         1.04 (0.74 to 1.40)            1.33 (0.92 to 1.87)         1.05 (0.82 to 1.36)         1.28 (0.92 to 1.74)         1.21 (0.87 to 1.64)         1.20 (0.81 to 1.73)         1.18 (0.88 to 1.54)         ---
   SES *v* medical treatment        0.89 (0.61 to 1.28)         0.84 (0.61 to 1.12)            1.08 (0.76 to 1.49)         0.82 (0.64 to 1.06)         1.05 (0.77 to 1.40)         0.98 (0.70 to 1.32)         0.90 (0.62 to 1.27)         0.94 (0.71 to 1.22)         ---
   E-ZES *v* medical treatment      0.80 (0.52 to 1.20)         0.73 (0.50 to 1.02)            0.99 (0.66 to 1·46)         0.76 (0.57 to 1.01)         0.76 (0.49 to 1.14)         0.84 (0.56 to 1.20)         0.75 (0.48 to 1.14)         0.80 (0.56 to 1.10)         ---
  New generation DES:                                                                                                                                                                                                                                                  
   R-ZES *v* medical treatment      0.78 (0.48 to 1.27)         0.75 (0.48 to 1.17)            NA                          0.73 (0.50 to 1.04)         NA                          0.85 (0.53 to 1.33)         0.79 (0.36 to 1.71)         0.82 (0.52 to 1.26)         ---
   EES *v* medical treatment        0.72 (0.49 to 1.07)         0.70 (0.50 to 0.96)            0.89 (0.60 to 1.27)         0.67 (0.51 to 0.89)         0.84 (0.57 to 1.22)         0.77 (0.54 to 1.07)         0.70 (0.46 to 1.06)         0.75 (0.55 to 1.01)         1.06 (0.51 to 2.19)
  Death or myocardial infarction:   63 trials with 174 559 PY   53 trials with 184 970 PY      61 trials with 190 173 PY   71 trials with 172 346 PY   71 trials with 148 563 PY   72 trials with 194 454 PY   49 trials with 204 959 PY   88 trials with 233 030 PY   
   CABG *v* medical treatment       0.79 (0.60 to 0.98)         0.81 (0.66 to 1.03)            0.82 (0.70 to 0.95)         ---                         0.83 (0.71 to 0.98)         0.77 (0.65 to 0.90)         0.80 (0.68 to 0.95)         0.81 (0.70 to 0.94)         0.76 (0.37 to 1.48)
   PTCA *v* medical treatment       0.86 (0.68 to 1.06)         0.87 (0.68 to 1.11)            0.84 (0.71 to 1.00)         0.87 (0.71 to 1.05)         0.83 (0.69 to 0.98)         0.81 (0.68 to 0.98)         0.79 (0.64 to 0.97)         0.83 (0.70 to 0.97)         0.69 (0.25 to 1.86)
   BMS *v* medical treatment        0.96 (0.76 to 1.17)         1.01 (0.84 to 1.18)            0.99 (0.85 to 1.14)         1.03 (0.89 to 1.18)         0.97 (0.81 to 1.11)         0.98 (0.83 to 1.15)         1.00 (0.84 to 1.16)         0.99 (0.85 to 1.12)         1.04 (0.75 to 1.30)
  Early generation DES:                                                                                                                                                                                                                                                
   PES *v* medical treatment        1.01 (0.77 to 1.26)         1.01 (0.79 to 1.25)            1.15 (0.89 to 1.42)         1.02 (0.82 to 1.22)         1.11 (0.88 to 1.36)         1.05 (0.86 to 1.27)         1.08 (0.87 to 1.35)         1.06 (0.87 to 1.27)         ---
   SES *v* medical treatment        0.88 (0.67 to 1.10)         0.92 (0.73 to 1.12)            1.02 (0.81 to 1.24)         0.91 (0.74 to 1.10)         1.04 (0.83 to 1.26)         0.97 (0.79 to 1.17)         0.97 (0.78 to 1.19)         0.96 (0.79 to 1.13)         ---
   E-ZES *v* medical treatment      0.83 (0.62 to 1.07)         0.82 (0.62 to 1.04)            0·97 (0.73 to 1.23)         0.83 (0.65 to 1.03)         0.79 (0.58 to 1.04)         0.86 (0.68 to 1.07)         0.87 (0.66 to 1.10)         0.85 (0.67 to 1.05)         ---
  New generation DES:                                                                                                                                                                                                                                                  
   R-ZES *v* medical treatment      0.77 (0.53 to 1.08)         0.79 (0.56 to 1.10)            NA                          0.78 (0.57 to 1.05)         NA                          0.81 (0.59 to 1.09)         0.79 (0.49 to 1.26)         0.81 (0.59 to 1.10)         ---
   EES *v* medical treatment        0.75 (0.56 to 0.96)         0.78 (0.60 to 0.97)            0.90 (0.49 to 1.63)         0.76 (0.60 to 0.93)         0.78 (0.58 to 1.03)         0.78 (0.62 to 0.96)         0.80 (0.62 to 1.03)         0.78 (0.63 to 0.96)         0.87 (0.43 to 1.74)
  Subsequent revascularisation:     66 trials with 183 001 PY   53 trials with 185 573 PY      65 trials with 189 933 PY   75 trials with 176 020 PY   79 trials with 155 514 PY   75 trials with 195 561 PY   49 trials with 205 311 PY   94 trials with 234 693 PY   
   CABG *v* medical treatment       0.16 (0.12 to 0.21)         0.17 (0.14 to 0.20)            0.17 (0.14 to 0.21)         ---                         0.16 (0.13 to 0.20)         0.15 (0.12 to 0.19)         0.18 (0.15 to 0.21)         0.16 (0.13 to 0.20)         0.17 (0.09 to 0.28)
   PTCA *v* medical treatment       0.87 (0.68 to 1.11)         0.87 (0.71 to 1.05)            0.93 (0.77 to 1.12)         0.92 (0.78 to 1.08)         0.97 (0.80 to 1.16)         0.94 (0.76 to 1.16)         0.93 (0.77 to 1.11)         0.97 (0.82 to 1.16)         0.87 (0.62 to 1.26)
   BMS *v* medical treatment        0.63 (0.50 to 0.81)         0.70 (0.61 to 0.81)            0.74 (0.62 to 0.88)         0.65 (0.56 to 0.76)         0.69 (0.58 to 0.82)         0.66 (0.53 to 0.82)         0.71 (0.61 to 0.82)         0.69 (0.59 to 0.82)         0.76 (0.49 to 1.23)
  Early generation DES:                                                                                                                                                                                                                                                
   PES *v* medical treatment        0.40 (0.30 to 0.54)         0.47 (0.39 to 0.58)            0.43 (0.33 to 0.57)         0.41 (0.33 to 0.50)         0.44 (0.34 to 0.57)         0.41 (0.32 to 0.54)         0.41 (0.33 to 0.52)         0.44 (0.35 to 0.55)         ---
   SES *v* medical treatment        0.26 (0.20 to 0.35)         0.32 (0.27 to 0.39)            0.29 (0.23 to 0.38)         0.26 (0.21 to 0.32)         0.28 (0.22 to 0.36)         0.27 (0.21 to 0.35)         0.33 (0.27 to 0.40)         0.29 (0.24 to 0.36)         ---
   E-ZES *v* medical treatment      0.34 (0.24 to 0.49)         0.40 (0.32 to 0.51)            0.39 (0.28 to 0.54)         0.34 (0.27 to 0.44)         0.38 (0.27 to 0.54)         0.36 (0.26 to 0.50)         0.39 (0.30 to 0.51)         0.38 (0.29 to 0.51)         ---
  New generation DES:                                                                                                                                                                                                                                                  
   R-ZES *v* medical treatment      0.24 (0.15 to 0.38)         0.29 (0.20 to 0.42)            NA                          0.25 (0.16 to 0.36)         NA                          0.25 (0.15 to 0.39)         0.31 (0.19 to 0.49)         0.26 (0.17 to 0.40)         ---
   EES *v* medical treatment        0.24 (0.18 to 0.33)         0.29 (0.23 to 0.36)            0.27 (0.07 to 0.95)         0.25 (0.20 to 0.31)         0.30 (0.22 to 0.42)         0.26 (0.19 to 0.34)         0.28 (0.22 to 0.36)         0.27 (0.21 to 0.35)         0.16 (0.09 to 0.28)

CABG=coronary artery bypass grafting; MI=myocardial infarction; PY=patient years; PTCA=percutaneous transluminal coronary angioplasty; BMS=bare metal stent; DES=drug eluting stent; PES=paclitaxel eluting stent; SES=sirolimus eluting stent; R-ZES=zotarolimus eluting (Resolute) stent; E-ZES=zotarolimus eluting (Endeavor) stent; EES=everolimus eluting stent.

\*Conventional random effects meta-analysis of direct randomised comparisons within trials.

Model fit, heterogeneity between trials, and consistency of the network
-----------------------------------------------------------------------

Model fit was adequate (see supplementary table 8) and heterogeneity between trials low for all outcomes (range of τ^2^ across outcomes 0.003 to 0.047; supplementary table 9). There was no evidence of inconsistency for the primary outcome of overall mortality (P for inconsistency=0.98), and 95% credibility intervals of all loop specific inconsistency factors overlapped the null (see supplementary figure 3). For the composite of death or myocardial infarction, 95% credibility intervals of two correlated loops, both involving coronary artery bypass grafting, did not cross the null, but the overall test for inconsistency was negative (P for inconsistency=0.27). For myocardial infarction, 95% credibility intervals of three loops did not overlap the null, two involving coronary artery bypass grafting, and the overall test for inconsistency was positive (P for inconsistency=0.015). For revascularisation, 95% credibility intervals of four loops did not overlap the null, three involving coronary artery bypass grafting, again with a positive overall test for inconsistency (P for inconsistency \<0.001). After restriction to contemporary trials, model fit remained adequate (see supplementary table 8) and heterogeneity between trials low for all outcomes (see supplementary table 9). Signals of inconsistency completely disappeared for myocardial infarction but persisted for revascularisation (see supplementary figure 4). Likely sources of inconsistency in the analysis of myocardial infarction were the 12 coronary artery bypass grafting trials initiated before 1999, which yielded a pooled rate ratio of 0.99 compared with medical treatment, balloon angioplasty or bare metal stent (95% credibility interval 0.81 to 1.20, τ^2^=0.050) compared with the six contemporary coronary artery bypass grafting trials, which yielded a pooled ratio of 0.49 compared with medical treatment or early generation drug eluting stents (0.40 to 0.60, τ^2^=0.000). The overall test for inconsistency became negative after exclusion of five coronary artery bypass grafting trials, which showed increases in the risk of myocardial infarction associated with coronary artery bypass grafting between 34% and 133% (see supplementary figure 5). Likely sources of inconsistency in the analysis of subsequent revascularisation were the FREEDOM and CARDia trials, which showed that the probability of subsequent revascularisation was reduced approximately three and six times with coronary artery bypass grafting compared with early generation drug eluting stents in people with diabetes, and the RESOLUTE China trial, which showed a fourfold reduction in subsequent revascularisations with the zotarolimus eluting (Resolute) stent compared with early generation drug eluting stents. The overall test for inconsistency remained positive after exclusion of these trials in the overall analysis but became negative in the analysis of contemporary trials (see supplementary figure 5), which showed only one inconsistent loop. Supplementary table 10 shows that estimates after exclusion of likely sources of inconsistency were similar to estimates from main analyses.

Discussion
==========

The salient findings of our network meta-analysis of 100 trials in 93 553 patients with stable coronary artery disease comparing revascularisation by coronary artery bypass grafting or various FDA approved percutaneous revascularisation technologies against medical treatment as initial strategy can be summarised as follows: coronary artery bypass grafting is associated with a statistically robust survival benefit compared with initial medical treatment; new generation drug eluting stents, but not balloon angioplasty, bare metal stents, or early generation drug eluting stents, are associated with improved survival compared with initial medical treatment; coronary artery bypass grafting reduces the risk of myocardial infarction compared with initial medical treatment; and the risk of subsequent revascularisation is noticeably reduced by coronary artery bypass grafting followed by new generation drug eluting stents, early generation drug eluting stents, and bare metal stents.

In secondary analyses of 88 contemporary trials in 85 720 patients, which were initiated in 1999 or later, we found these results confirmed, with the exception of myocardial infarction, which showed considerably more pronounced treatment benefits of coronary artery bypass grafting and statistically more robust benefits of everolimus eluting stents. Since signals of inconsistency observed in the primary analysis of myocardial infarction completely disappeared in this secondary analysis, we deem the 52% reduction in the risk of myocardial infarction observed in the secondary analysis a more reliable estimate of the effects of contemporary revascularisation with coronary artery bypass grafting on myocardial infarction than the 21% reduction found in the primary analysis.

The most important finding of the present analysis is that several revascularisation techniques---notably, coronary artery bypass grafting and new generation drug eluting stents---are associated with improved survival compared with an initial strategy of medical treatment alone among patients with stable coronary artery disease. The survival benefit over medical treatment is well established for coronary artery bypass grafting[@ref5] but novel for percutaneous coronary intervention with new generation drug eluting stents. Our study corroborates previous reports on coronary artery bypass grafting and extends the observed benefit to contemporaneous study populations included in more recent trials with more effective medical regimens,[@ref28] [@ref33] increased use of arterial bypass grafts, and improved perioperative management, providing a statistically more robust estimate of the associated survival benefit.

The mechanism underlying the survival benefit of both coronary artery bypass grafting and new generation drug eluting stents compared with initial medical treatment seems to be related in part to a lower risk of myocardial infarction. The lower risk of myocardial infarction with coronary artery bypass grafting compared with medical treatment is explained by the protective effect of patent grafts against proximal vessel occlusions.[@ref43] Similarly, new generation drug eluting stents---specifically everolimus eluting stents---were associated with a trend towards a lower risk of myocardial infarction. Compared with previously used percutaneous revascularisation techniques, new generation drug eluting stents have been consistently shown to afford a reduction in the risk of myocardial infarction and stent thrombosis.[@ref44] A recent network meta-analysis reported a profound reduction of stent thrombosis with everolimus eluting stents compared not only with other drug eluting stents but also with bare metal stents[@ref45]---a finding that is supported by experimental evidence of antithrombotic properties of everolimus eluting stents.[@ref46] Moreover, direct comparisons of everolimus eluting stents with early generation paclitaxel eluting stents and to a lesser degree with sirolimus eluting stents have shown a lower risk of myocardial infarction with everolimus eluting stents.[@ref25] [@ref47] It is therefore likely that the improved safety profile of new generation drug eluting stents in terms of myocardial infarction and stent thrombosis translates into improved survival compared with initial medical treatment by providing effective revascularisation without the associated risk of stent related adverse effects.

Our study provides a nuanced interpretation of the benefit of percutaneous coronary intervention techniques over initial medical treatment in terms of survival and the risk of myocardial infarction, which seems to be directly related to the device type used for revascularisation. While older technologies conferred no apparent benefit compared with medical treatment, the advent of new generation drug eluting stents apparently resulted in a survival benefit. A previous network meta-analysis comparing percutaneous coronary intervention with medical treatment was limited to the inclusion of early generation paclitaxel eluting stents and sirolimus eluting stents and observed no benefit in relation to medical treatment in terms of survival and myocardial infarction.[@ref6] The present study importantly extends this analysis by the addition of new generation FDA approved drug eluting stents as well as comparisons with coronary artery bypass grafting. Against this background, the missing survival benefit of percutaneous coronary intervention compared with medical treatment in the COURAGE trial has to be interpreted in view of the device used---namely, bare metal stents.[@ref13] More recent studies comparing initial medical treatment with new generation drug eluting stents, such as ISCHEMIA (ClinicalTrials.gov NCT01471522), have the potential to disclose a benefit in ischaemic endpoints in favour of drug eluting stents. Enrolment into FAME II was interrupted early after interim analyses disclosed an excess of primary endpoint events among medically treated patients largely driven by urgent revascularisation procedures, which in about half of cases had evidence of ongoing ischaemia on electrocadiography or myocardial infarction.[@ref32]

Coronary artery bypass grafting resulted in the strongest reduction in the need for revascularisation compared with medical treatment (\>80%), which was superior to any percutaneous coronary intervention technology, including new generation drug eluting stents. Among percutaneous revascularisation technologies, continuous progress in the need of revascularisation compared with medical treatment was observed over time, which was reduced by approximately 30% with bare metal stents, 60% with early generation paclitaxel eluting stents and zotarolimus eluting (Endeavor) stent, and more than 70% with early generation sirolimus eluting stents and new generation everolimus eluting stents and the zotarolimus eluting (Resolute) stent compared with medical treatment. Of note, the potent reduction in revascularisation with new generation drug eluting stents was not associated with any safety concerns. In fact, new generation everolimus eluting stents combined one of the best efficacy profiles among drug eluting stents with improved survival and a trend towards a lower risk of myocardial infarction compared with medical treatment alone. Notwithstanding, even new generation drug eluting stents remained less effective than coronary artery bypass grafting for risk of subsequent revascularisation. This is important as percutaneous coronary intervention irrespective of device type results in less complete revascularisation. Therefore the selection of revascularisation modality remains important, particularly among patients with advanced coronary artery disease.

Limitations of this study
-------------------------

The present analysis has to be interpreted in view of several limitations. Firstly, any revascularisation technique, coronary artery bypass grafting, or percutaneous coronary intervention is associated with a risk of periprocedural myocardial infarction, which is typically diagnosed by increases in biomarkers despite the absence of symptoms or electrocardiographic changes, and the prognostic importance of periprocedural myocardial infarction remains disputed. In our analysis we were, however, unable to distinguish between periprocedural and spontaneous myocardial infarction. Several studies indicate that preprocedural rather than post-procedural increases in biomarkers are associated with impaired prognosis[@ref48] and that only large periprocedural myocardial infarctions are associated with poor outcome.[@ref49] This is of importance, as a recent meta-analysis comparing percutaneous coronary intervention with initial medical treatment reported a lower risk of spontaneous myocardial infarction with percutaneous coronary intervention, which was offset by an increased risk of periprocedural myocardial infarction.[@ref10] A distinction of different types of myocardial infarction could therefore have improved our understanding of the mechanisms behind the observed survival benefit with coronary artery bypass grafting and new generation drug eluting stents. Since periprocedural myocardial infarctions preferentially occur among patients undergoing revascularisation, a restriction of the analysis to spontaneous myocardial infarction would have resulted in a more pronounced reduction in myocardial infarction with revascularisation.

Secondly, our analysis was based on the intention to treat principle, with randomised patients analysed in the group to which they were originally allocated irrespective of subsequent crossovers to revascularisation among patients allocated to medical treatment. This will have resulted in an underestimation of the true benefits of revascularisation.

Thirdly, some will argue that the inclusion of stable patients with recent myocardial infarction and trials with all comer populations including patients with acute coronary syndromes may have biased results in favour of revascularisation. However, a sensitivity analysis excluding trials in these patient populations yielded much the same results as the primary analysis (table 3).

Fourthly, the trials included in the network meta-analysis were performed over a period of several decades, during which clinical practice and optimal medical treatment for patients with coronary artery disease have evolved. Although we cannot exclude that changes in medical treatment over time have affected the results of this analysis, we deem this unlikely. Our analysis preserves randomised treatment comparisons within trials, statistical heterogeneity was low for all outcomes, our model with its assumptions fitted the trial data adequately, and there was no evidence of inconsistency for the primary outcome of all-cause mortality. Sources of residual inconsistency for myocardial infarction and subsequent revascularisation were explained by reasons other than concomitant medical treatment.

Fifthly, the results of the current analysis are derived from patient populations enrolled into randomised trials and may not necessarily apply to all patients encountered in routine clinical practice. Moreover, diagnostic angiography preceded randomisation in most strategy trials comparing revascularisation with medical treatment, which is likely to have resulted in the exclusion of higher risk patients.

Sixthly, in the absence of individual patient data we were forced to assume in the analysis that event rates in each trial arm were constant over time, when in reality event rates are likely to be higher during the first 30 days after randomisation.[@ref35] A sensitivity analysis of risk ratios, which does not make this assumption, showed nearly identical results, however. In addition, we assumed that the between trial variance τ^2^ is equal across comparisons, as is commonly done in network meta-analysis. This may be criticised, but was inevitable, since it allowed us to borrow strength for estimating heterogeneity across different comparisons, when some comparisons were based on a few or even a single trial only.[@ref50]

Seventhly, the absence of individual patient data means that the present analysis provides average risk estimates and does not allow the evaluation of specific subgroups. It remains to be determined whether the observed treatment effects are consistent among specific high risk patient populations, such as patients with multivessel disease, diabetes, or left ventricular dysfunction, and it cannot be excluded that the advantages of coronary artery bypass grafting are more pronounced in certain subgroups of patients than observed on average in our analysis.

Finally, we were unable to distinguish between the angiographic extent of severity of coronary artery disease and functional extent of ischaemic myocardium from the data extracted for this analysis. Recent changes in clinical practice guidelines, however, highlight the importance of functional lesion severity before revascularisation. An individual patient data network meta-analysis, even though demanding, would enable the limitations discussed here to be addressed.

Using network meta-analysis, we included data from 100 trials in 93 553 patients. Our model fully preserved randomisation within each trial but integrated evidence from direct and indirect comparisons to borrow strength from the entire network of trials.[@ref35] Our approach resulted in a gain in statistical precision, particularly for mortality and myocardial infarction that had only been imprecisely estimated in previous analyses. Our model is based on relative treatment effects (log rate ratios), and variations in patient characteristics and medical co-interventions between trials are accounted for in the analysis by preserving randomised comparisons within each trial. Network meta-analysis makes similar assumptions to standard meta-analysis, but requires that these assumptions hold over the entire set of trials of the network. Additional assumptions, which are specific for network meta-analysis, are that the model fits the data and that the network of trials is consistent, with no relevant differences in estimates between direct and indirect comparisons. In view of low statistical heterogeneity, a lack of inconsistency, and excellent model fit, it is likely that these assumptions were fully satisfied over the entire set of trials covering a period of more than 30 years for the primary outcome of all cause mortality. For myocardial infarction, the secondary analysis restricted to contemporaneous trials is likely to be more reliable than the primary analysis of all trials, since signals of inconsistency initially found for myocardial infarction completely disappeared in the restricted analysis. For the outcome of subsequent revascularisation, we found evidence of inconsistency in both primary and secondary analysis, even though model fit was adequate and heterogeneity between trials low. In view of the magnitude of observed average effects, this does not, however, invalidate our conclusions that coronary artery bypass grafting is associated with the largest benefits on this outcome, followed by new generation drug eluting stents.

Conclusions
-----------

Among patients with stable coronary artery disease, coronary artery bypass grafting reduces the risk of death, myocardial infarction, and the need for revascularisation compared with medical treatment. All stent based percutaneous coronary interventions reduce the need for revascularisation to a variable degree. Our results provide evidence for improved survival with new generation drug eluting stents but no other percutaneous coronary intervention compared with medical treatment.

### What is already known on this topic

1.  Coronary artery bypass grafting has been shown to improve survival compared with a strategy of initial medical treatment among patients with stable coronary artery disease

2.  Percutaneous coronary intervention compared with a strategy of initial medical treatment has not been associated with a survival advantage to date

3.  Clinical outcomes have been improved by revascularisation techniques with systematic use of the internal mammary artery in case of coronary artery bypass grafting and important transitions in case of percutaneous revascularisation technology

### What this study adds

1.  Coronary artery bypass grafting and new generation drug eluting stents are associated with a survival benefit compared with a strategy of initial medical treatment

2.  Coronary artery bypass grafting reduces the risk of myocardial infarction, and new generation everolimus eluting stents are associated with a trend towards a reduced risk of myocardial infarction compared with initial medical treatment

3.  The risk of subsequent revascularisation is noticeably reduced by coronary artery bypass grafting followed by new generation drug eluting stents, early generation drug eluting stents, and bare metal stents
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